MedTrace Logo

Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-29

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Acral Lentiginous Melanoma
  • Cutaneous Nodular Melanoma
  • Lentigo Maligna Melanoma
  • Low-CSD Melanoma
  • Mucosal Melanoma
  • Recurrent Melanoma
  • Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

DRUG

Dinaciclib

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Christopher D Lao · SWOG Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-01
Primary Completion
2013-10-22
Completion
2027-03-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937937 on ClinicalTrials.gov